Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting

by F. Roghmann, R. Wirtz, A. Santiago-Walker, J. Jarczyk, M.C. Kriegmair, T.S. Worst, D. Sikic, S. Wach, H. Taubert, V. Weyerer, R. Stoehr, K. Tully, F. Zengerling, C. Bolenz, J. Breyer, M. Burger, S. Porubsky, A. Hartmann, P. Erben, M. Eckstein, H. Jütte
Published 2020-07-01